I read with great interest the review article by Lipsky et al1 dealing with unresolved issues in the role of cyclooxygenase (COX) isoforms in normal physiologic processes and disease. The authors inferred from the available data that COX-2–specific inhibitors may have new therapeutic targets, such as adenomatous polyposis and colon cancer, and new untoward effects, such as thromboembolic cardiovascular adverse events, as compared with conventional nonsteroidal anti-inflammatory drugs (NSAIDs), which block both COX-1 and COX-2 activity.
Bannwarth B. Are COX-2 Inhibitors as Effective as Conventional NSAIDs in Acute Pain States?. Arch Intern Med. 2001;161(1):127-128. doi: